Referral: Parenteral iron-containing medicinal products, ferric carboxymaltose,ferric derisomaltose,ferric gluconate,ferric hydroxide polymaltose complex,iron...

Read full

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026

about 2 hours ago

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August -...

Read full

Framework for interaction with pharmaceutical industry stakeholders

about 4 hours ago

Framework for interaction with pharmaceutical industry stakeholders

Read full

Pharmaceutical industry: Getting involved in EMA activities

about 4 hours ago

Pharmaceutical industry: Getting involved in EMA activities

Read full

Opinion/decision on a Paediatric investigation plan (PIP): Skyclarys, omaveloxolone, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic diso

about 3 hours ago

Opinion/decision on a Paediatric investigation plan (PIP): Skyclarys, omaveloxolone, decision type: P...

Read full

Or log in

Everything you care about in one place

What's new

Latest posts

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

Union Product Database: release notes

Pharmacogenomics

Release notes - production release version 1.7.2633 - 4 September 2026 - Veterinary Medicinal Products Regulation: Union Product Database

Human medicines European public assessment report (EPAR): Miglustat Dipharma, miglustat, Date of authorisation: 18/02/2019, Revision: 9, Status: Authorised

Guidance for applicants on how to submit ePI in centralised procedures

Executive Director's speech at Duke-NUS Medical School in Singapore

Referral: Parenteral iron-containing medicinal products, ferric carboxymaltose,ferric derisomaltose,ferric gluconate,ferric hydroxide polymaltose complex,iron dextran,iron sucrose Article 31 referrals Procedure started

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026

Framework for interaction with pharmaceutical industry stakeholders

Pharmaceutical industry: Getting involved in EMA activities

Opinion/decision on a Paediatric investigation plan (PIP): Skyclarys, omaveloxolone, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic diso

Try Feeder for free